Yayın: Sequential vs Myeloablative vs Reduced Intensity Conditioning for Patients with Myelodysplastic Syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A Retrospective Study by the Chronic Malignancies Working Party of the EBMT
| dc.contributor.author | Potter, V. | |
| dc.contributor.author | Gras, L. | |
| dc.contributor.author | Koster, L. | |
| dc.contributor.author | Kroger, N. | |
| dc.contributor.author | Sockel, K. | |
| dc.contributor.author | Ganser, A. | |
| dc.contributor.author | Finke, J. | |
| dc.contributor.author | Labussiere-Wallet, H. | |
| dc.contributor.author | Peffault de Latour, R. | |
| dc.contributor.author | Koc, Y. | |
| dc.contributor.author | Salmenniemi, U. | |
| dc.contributor.author | Smidstrup Friis, L. | |
| dc.contributor.author | Jindra, P. | |
| dc.contributor.author | Schroeder, T. | |
| dc.contributor.author | Tischer, J. | |
| dc.contributor.author | Arat, M. | |
| dc.contributor.author | Pascual Cascon, M. | |
| dc.contributor.author | de Wreede, L. C. | |
| dc.contributor.author | Hayden, P. | |
| dc.contributor.author | Raj, K. | |
| dc.contributor.author | Drozd-Sokolowska, J. | |
| dc.contributor.author | Scheid, C. | |
| dc.contributor.author | McLornan, D. P. | |
| dc.contributor.author | Robin, M. | |
| dc.contributor.author | Yakoub-Agha, I. | |
| dc.date.accessioned | 2026-01-24T22:55:06Z | |
| dc.date.issued | 2023-03-07 | |
| dc.description.abstract | <title>Abstract</title> <p>The optimal conditioning for patients with higher risk MDS receiving potentially curative allogeneic haematopoietic stem cell transplant(allo-HCT) remains to be defined. This is particularly the case for patients with excess of blasts at time of allo-HCT. Sequential(Seq) conditioning, whereby chemotherapy is followed rapidly by transplant conditioning, offers an opportunity to decrease disease burden, potentially improving outcomes allo-HCT outcomes. Herein we present the only analysis comparing Seq to myeloablative(MAC) and reduced intensity conditioning(RIC) specifically focussed on MDS patients with excess of blasts at allo-HCT. 303 patients were identified in the EBMT registry, receiving RIC(n=158,) Seq(n=105,), and MAC(n=40, ). Median follow-up was 67.2 months and median age at allo-HCT was 59.5 years(IQR 53.5 - 65.6). For the entire cohort, 3yr overall survival(OS) was 50%(95% CI45-56%) and relapse free survival(RFS) 45%(95%CI 40-51%). No differences in outcomes were observed per protocol with respect to OS and RFS. On multivariable analysis, lower performance status, worse IPSS-R cytogenetics, sibling donor (compared to 8/8 MUD) and >20% blasts at allo-HCT were associated with worse outcomes. In conclusion, the Seq protocol did little to influence the outcome in this high-risk group of patients, with outcomes mostly determined by baseline disease risk and patient characteristics such as performance status.</p> | |
| dc.description.uri | https://doi.org/10.21203/rs.3.rs-2604480/v1 | |
| dc.description.uri | https://doi.org/10.1038/s41409-023-02111-3 | |
| dc.description.uri | https://pubmed.ncbi.nlm.nih.gov/37993503 | |
| dc.description.uri | https://hal.univ-lille.fr/hal-04512607v1 | |
| dc.description.uri | https://hdl.handle.net/1887/3748475 | |
| dc.description.uri | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85177460879 | |
| dc.description.uri | https://www.researchsquare.com/article/rs-2604480/v1 | |
| dc.description.uri | https://www.ncbi.nlm.nih.gov/pubmed/37993503 | |
| dc.description.uri | https://doi.org/https://doi.org/10.1038/s41409-023-02111-3 | |
| dc.identifier.doi | 10.21203/rs.3.rs-2604480/v1 | |
| dc.identifier.eissn | 1476-5365 | |
| dc.identifier.endpage | 231 | |
| dc.identifier.issn | 0268-3369 | |
| dc.identifier.openaire | doi_dedup___::31e410304f47490b571d326c77530e8d | |
| dc.identifier.orcid | 0000-0001-5103-9966 | |
| dc.identifier.orcid | 0000-0002-1799-5927 | |
| dc.identifier.orcid | 0000-0002-8415-7069 | |
| dc.identifier.orcid | 0000-0002-1653-7959 | |
| dc.identifier.orcid | 0000-0003-1821-1976 | |
| dc.identifier.orcid | 0000-0003-2039-8557 | |
| dc.identifier.orcid | 0000-0002-7667-9369 | |
| dc.identifier.orcid | 0000-0003-1374-4503 | |
| dc.identifier.orcid | 0000-0002-8258-354x | |
| dc.identifier.orcid | 0000-0002-4562-6264 | |
| dc.identifier.orcid | 0000-0003-1224-091x | |
| dc.identifier.orcid | 0000-0003-1388-9876 | |
| dc.identifier.orcid | 0000-0003-4524-8782 | |
| dc.identifier.startpage | 224 | |
| dc.identifier.uri | https://hdl.handle.net/11527/39160 | |
| dc.identifier.volume | 59 | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.relation.ispartof | Bone Marrow Transplantation | |
| dc.rights | OPEN | |
| dc.sdg.type | Goal 3: Good Health and Well-being | |
| dc.subject | Transplantation Conditioning | |
| dc.subject | Medizin | |
| dc.subject | Hematopoietic Stem Cell Transplantation | |
| dc.subject | Graft vs Host Disease | |
| dc.subject | Middle Aged | |
| dc.subject | [SDV] Life Sciences [q-bio] | |
| dc.subject | Myelodysplastic Syndromes | |
| dc.subject | Chronic Disease | |
| dc.subject | Humans | |
| dc.subject | Transplantation, Homologous | |
| dc.subject | Neoplasm Recurrence, Local | |
| dc.subject | Aged | |
| dc.subject | Retrospective Studies | |
| dc.title | Sequential vs Myeloablative vs Reduced Intensity Conditioning for Patients with Myelodysplastic Syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A Retrospective Study by the Chronic Malignancies Working Party of the EBMT | |
| dc.type | Article | |
| dspace.entity.type | Publication |